http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003124615-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_98ec116ec7b433b65becf5847b31e058 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-975 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C10G19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B63-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C10L3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C10L3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B63-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C10G19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 |
| filingDate | 2002-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ced8e244a0bee7ba7c97ec11842c83e3 |
| publicationDate | 2003-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003124615-A1 |
| titleOfInvention | Thromoboxane B2 metabolite and methods for regulating aspirin-related platelet action |
| abstract | Disclosed are unique methods for identifying the lowest, yet optimal, aspirin doses for patients. These methods are also characterized as having little to no aspirin-related side-effects. These methods may be used pre-as well as post-thrombotic event, and employs a patient's urinary thromboxane B 2 metabolic levels (e.g., 11-dehydrothromboxane B 2 ), to identify the patient's platelet activation level. A patient's urinary thromboxane B 2 metabolic level is then used to calculate and appropriate and individualized treatment effective for utilizing platelet activation. Kits for utilizing this technique are also provided. In yet another particular aspect, the invention provides a method for utilizing a random urine sample obtained from a patient to determine whether a patient or particular individual's current dosage of aspirin is providing an adequate and appropriate level of inhibition of platelet activation levels, as compared to inhibition levels observed in individuals not taking aspirin. Also provided are methods that include use of neutraceuticals in combination with the aspirin dosing regimen of the invention. The present invention further includes calibrant preparations. In some embodiments, these calibrants comprise urine, particularly human urine that is identified in repeated trials to provide a consistent and reproduceable level of thromboxane B 2 metabolite. As such, they function as control preparations that reduce error from intra-assay sampling measurements. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010184084-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9506938-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111443201-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7081347-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7935498-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004115735-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010041079-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111735809-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008009024-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7595201-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004126826-A1 |
| priorityDate | 1999-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 188.